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Eye 0.435 0.404 7.2 Kidney 1 0.321 0.350 -9.2 
Heart0.740 0.757 -2.3 Kidney 2 0.345 0.366 -6.1 
Bone 
1 2.054 2.039 0.7 Lung 1 0.901 0.936 -4.0 
Bone 
2 2.046 2.024 1.1 Lung 2 1.063 1.116 -5.1 
Bone 
3 2.102 1.997 5.0 Lung 3 0.464 0.492 -6.2 
Bone 
4 2.058 2.018 1.9 Lung 4 0.573 0.584 -2.0 
Bone 
5 2.079 2.007 3.5 Lung 5 0.531 0.545 -2.7 
Bone 
6 1.997 1.996 0.1 Lung 6 0.661 0.611 7.6 
Bone 
7 1.995 1.993 0.1 Lung 7 0.593 0.641 -8.1 
Bone 
8 1.979 2.062 -4.2 Lung 8 0.894 0.829 7.3 
Bone 
9 2.042 1.988 2.6 Lung 9 0.515 0.531 -3.0 
    
Lung 
10 0.518 0.564 -9.0 
    
Lung 
11 0.575 0.553 3.9 
 
Conclusions: The mean measured dose to the lungs was only 6.02 Gy, 
whereas most studies of TBI have reported a range of 8-10 Gy. TMI-HT 
delivers lower doses vs. conventional total body irradiation, thus 
providing additional support for this technique. HT-TMI reduces the 
dose delivered to the lungs to levels that are much lower than those 
reported for TBI with a conventional linear accelerator. These results 
provide additional support for the use of TMI in conditioning regimens 
for bone marrow transplantation.  
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Purpose/Objective: Portal Dosimetry (PD) is a convenient tool for 
rapid and reliable pre-treatment verification of IMRT and VMAT plans. 
Varian's PD solution requires commissioning of a dedicated prediction 
algorithm as well as the calibration of the amorphous Silicon (aSi) 
imager. These procedures involve the individual configuration for each 
system and are limited by inherent shortcomings such as imperfect 
beam profile correction and backscatter effects. For these reasons we 
propose generic configuration data per system type and beam energy 
including improved beam profile and backscatter correction. This 
work aims for evaluating the applicability of this generic configuration 
data to different Varian aSi/Linac combinations by comparing 
predicted and acquired PD images with respect to output factor (OF), 
beam profile and backscatter correction. 
Materials and Methods: The backscatter effect is field size 
dependent, thus implementing the backscatter correction using 
calibration data required a trade-off: Good performance for small to 
medium (clinically more relevant) field sizes versus reduced 
performance for larger field sizes. The PD solution was configured on 
11 Varian systems (3 Unique, 8 Clinac) at 9 different sites for beam 
energies of 6 MV (n=8), 15 MV (n=2) and 18MV (n=3) using the generic 
PD configuration package. Pre-treatment verification plans were 
created to calculate predicted PD images for square fields of size 3 x 
3 cm2 to 30 x 30 cm2. Subsequently, the corresponding PD images 
were acquired. 
Performance of the configured PD solution was evaluated with respect 
to: (i) OFs by calculating the rel. difference (acquired vs. predicted 
PD image) of the central axis dose values, (ii) beam profile correction 
by calculating the mean rel. difference of the central cross-line 
profiles in the flat field region (80% area within field limits) and (iii) 
backscatter correction by calculating the maximum rel. difference of 
the central half in-line profile in the flat field region (Fig. 1a). 
 
  
Results: The analysis of 6MV Clinac data (Fig. 1b) revealed that for 
OFs and beam profile correction the rel. differences were found to be 
within ±1% for all field sizes, while the backscatter correction was 
found to be within ±1.5% for field sizes up to 15 x 15 cm2. For the 6MV 
Unique data and 15MV Clinac data the same limits were met except 
for the backscatter correction of the smallest field size (3 x 3 cm2). 
The 18MV Clinac data revealed rel. differences smaller than ±1% for 
both OFs and beam profile correction, while not all field sizes (4 x 4 
cm2 and 5 x 5 cm2) met the ±1.5% limit for the backscatter correction. 
Conclusions: The use of generic configuration data appears to be 
feasible for the Varian PD solution allowing for a simplified 
configuration process and the easy implementation of essential 
improvements. Further data at high beam energies as well as for 
dynamic MLC fields (IMRT and VMAT) are required to support the 
promising results obtained in this preliminary study. 
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Purpose/Objective: To evaluate the possibility to use an amorphus 
silicon portal imager as pre-treatment quality assurance of RapidArc 
plans with flattening filter free (FFF) beams. 
Materials and Methods: On Varian TrueBeam linac, the PV-aS1000 
detector response was investigated for 6 and 10 MV FFF beams. With 
an adequate source to detector distance, e.g. SDD=150 cm, even with 
the maximum dose rate of 1400 and 2400 MU/min the integrated 
image does not present saturation. This allows its usage for dosimetric 
evaluations also for FFF beams. The GLAaS algorithm was originally 
developed to convert portal imager integrated readings into absorbed 
dose to water, and was validated for IMRT and RapidArc (the Varian 
VMAT) pre-treatment quality assurance for standard flattened beams. 
The algorithm was adapted to FFF beams and validated for open as 
well as for modulated beams. In this study it was used to evaluate 
RapidArc pre-treament acquisitions. Five different clinical FFF 
RapidArc plans were selected and recalculated for both 6 and 10 MV 
FFF. The maximum dose rate was set for each energy. Dose 
prescriptions ranged from 7 to18 Gy/fraction. Pre-treatment QA 
deliveries were performed on four different TrueBeam machines (two 
equipped with a high-definition MLC, HD-120MLC, and two with a 
standard Millenium 120-MLC). QA evaluation was based on gamma 
index,using distance to agreement and dose difference criteria of 
3mm/3% and 2mm/2%. 2D dose maps were evaluated also through 
profiles. 
Results: The percentage of points passing the gamma criteria (gamma 
agreement index GAI) were collected for all deliveries.For 3mm/3% 
criteria, GAI evaluated on the field area was 97.9±2.5% and and 
98.6±1.6% for 6 and10 MV FFF respectively.For 2mm/2% criteria, GAI 
evaluated on the field area was 92.0±3.5% and and 96.6±4.3% for 6 
and10 MV FFF respectively. 
Conclusions: The possibility to use the Portal Vision as pre-treatment 
QA for RapidArc for FFF beams gives advantages that can be 
summarised in three points: 1) verification of absorbed dose 
calculation, 2) fast acquisition, 3) improved resolution at SDD=150 cm, 
particularly interesting in hypofractionated treatment, where small 
fields are mostly used. Gamma results presented fully satisfactory 
results in line with standard flattened beams.  
